Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use.
作者信息
Scrijvers D, Roila F
机构信息
Department of Medical Oncology, Ziekenhuis Antwerpen Middelheim, Antwerp, Belgium.
出版信息
Ann Oncol. 2009 May;20 Suppl 4:159-61. doi: 10.1093/annonc/mdp161.
PMID:19454443
Abstract
摘要
相似文献
1
Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use.
Ann Oncol. 2009 May;20 Suppl 4:159-61. doi: 10.1093/annonc/mdp161.
2
Management of venous thromboembolism in cancer patients: ESMO clinical recommendations.
Ann Oncol. 2009 May;20 Suppl 4:182-4. doi: 10.1093/annonc/mdp167.
3
Management of cancer pain: ESMO clinical recommendations.
Ann Oncol. 2009 May;20 Suppl 4:170-3. doi: 10.1093/annonc/mdp164.
4
Familial colorectal cancer risk: ESMO clinical recommendations.
Ann Oncol. 2009 May;20 Suppl 4:51-3. doi: 10.1093/annonc/mdp127.
5
Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:123-5. doi: 10.1093/annonc/mdp150.
6
Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:49-50. doi: 10.1093/annonc/mdp126.
7
Pancreatic cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:37-40. doi: 10.1093/annonc/mdp123.
8
Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:54-6. doi: 10.1093/annonc/mdp128.
9
Anal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:57-60. doi: 10.1093/annonc/mdp129.
10
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:34-6. doi: 10.1093/annonc/mdp122.
引用本文的文献
1
Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.
BMC Cancer. 2013 Jul 10;13:340. doi: 10.1186/1471-2407-13-340.
2
Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.
Clin Transl Oncol. 2013 Jun;15(6):477-83. doi: 10.1007/s12094-012-0953-5. Epub 2012 Dec 19.
3
Risk management of biosimilars in oncology: each medicine is a work in progress.
Target Oncol. 2012 Mar;7 Suppl 1(Suppl 1):S43-9. doi: 10.1007/s11523-011-0188-3. Epub 2012 Jan 25.
4
Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia.
Support Care Cancer. 2010 Dec;18(12):1515-20. doi: 10.1007/s00520-009-0773-5. Epub 2009 Nov 17.
Zotero 插件